$7 billion Deliveroo is preparing for a blockbuster float. Here's the who's who of executives and investors steering it to IPO.

Financial world news, market analysis, investment scam prevention tips and more ✔️ Learn all there is to know about the asset management industry. This magazine is crafted specifically for those who are interested in diving into the global asset management world. Deliveroo CEO Will Shu in France in 2018. Amazon-backed food delivery startup Deliveroo is anticipated to float in 2021, marking a rare high-profile British technology float.Like rival Uber Eats, Deliveroo allows consumers to order restaurant food via an app and relies on a network of gig economy cyclists and motorcyclists to make the deliveries. During the coronavirus pandemic, it has expanded into grocery delivery. The firm doesn't operate in the US, but around Europe and parts of Asia.The company was founded in 2012 by current CEO Will Shu and Greg Orlowski, who departed the business in 2016. According to its most recent financial filings, the company is still loss-making, albeit posting healthy profit margins and revenue growth. Deliveroo's float will continue the US trend of buzzy tech firms floating before they consistently turn a profit.Ahead of its expected float, Insider looked at the 12 board members steering the firm towards a float - a mix of company executives, its biggest investors, and seasoned corporate execs.The board is overwhelmingly men, counting just one woman, chair Claudia Arney.Got a tip about Deliveroo? Contact the reporter behind this story, Shona Ghosh, at sghosh@businessinsider.com or +447412061471 for Signal/WhatsApp.Cofounder and CEO Will Shu Deliveroo To keep reading about $7 billion Deliveroo is preparing for a blockbuster float. Here's the who's who of executives and investors steering it to IPO., Click on the link. Seoul, Korea
http://dlvr.it/RrDd1M

Comments

Post a Comment

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Image
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said first participants have been dosed in a Phase I trial of AZD7442 for the prevention and treatment of COVID-19. The trial will evaluate the safety, tolerability and pharmacokinetics of AZD7442. It will include up to 48 healthy participants in the UK aged 18 to 55 years. AZD7442 is a combination of two monoclonal antibodies derived from convalescent patients with SARS-CoV-2 infection. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the mAbs were optimised by AstraZeneca. Data readout from the trial is anticipated in the second half of 2020. To keep reading about AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts, Click on the link. Seoul, Korea http://dlvr.it/RfHgSK
Read more

Coronavirus Hasn't Diminished Tech Stocks' Allure

Image
FYI: By Caitlin McCabe Caitlin McCabe The Wall Street Journal Biography caitlin.mccabe@wsj.com Updated April 20, 2020 6:14 pm ET The FANG trade hasn’t lost its bite. Big technology stocks are again charging to new heights and propelling the broader stock market, which is swiftly rebounding after a punishing selloff. The NYSE FANG+ index—which comprises Facebook Inc., FB -0.56% Amazon.com Inc., AMZN 0.78% Netflix Inc. NFLX 3.44% and Google parent Alphabet Inc., GOOG -1.30% along with Apple Inc., AAPL -2.08% Twitter Inc., Tesla Inc., TSLA -1.00% Nvidia Corp. NVDA -1.80% and the Chinese behemoths Alibaba Group Holding Ltd. and Baidu Inc. —is up 11% year-to-date after a dramatic rally last week. The four FANG stocks added $251 billion in market value last week, their biggest gain on record dating to Facebook’s 2012 initial public offering. The S&P 500, in comparison, is down 13% in 2020 but has r
Read more

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. SHANGHAI, March 28, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail to respond to the standard therapy has met the primary endpoint. Henlius plans to file a New Drug Application (NDA) to the National Drug Products Administration (NMPA) for the treatment of MSI-H solid tumours based on the results from the Phase 2 trial of HLX10, which will be presented at upcoming medical conferences. Professor Shukui Qin of No.81 Hospital of People's Liberation Army and Professor Jin Li of Shanghai East Hospital affiliated to Shang
Read more